PTGES and Peritoneal Fibrosis: These findings suggest that targeting mPGES-1 may attenuate the progression of peritoneal fibrosis; however, the use of mPGES-1 inhibitors in clinical practice is limited because they also inhibit physiologic functions of PGE2.